Last checked at 7 Nov 2018 07:00
ECO Animal Health Group plc
(AIM: EAH)
ECO Animal Health joint venture for the registration and commercialization of swine vaccine products extends scope to include Japan and Brazil.
ECO Animal Health Ltd (ECO), a wholly owned subsidiary of ECO Animal Health Group plc, and Pharmgate LLC (Pharmgate) of Wilmington, North Carolina, USA are pleased to announce that the scope of their new joint venture established in April 2018, ECO-Pharm Limited, based in the Republic of Ireland has now been extended.
ECO-Pharm Limited will now be responsible for the registration, marketing, sale and distribution of a number of Pharmgate LLC swine vaccine products in the United Kingdom, the European Union and the Commonwealth of Independent States, Japan and Brazil. It is expected that further vaccine products will flow from our biologicals research and development pipeline.
ECO and Pharmgate have jointly established Pharmgate Animal Health in the United States of America (2010) and Canada (2011). These successful operations market their owners’ range of extensively used medicated feed additives and innovative new therapeutic compounds for livestock and poultry. Pharmgate has recently licensed and commercialised their swine vaccine products in North America through these joint ventures.
Peter Lawrence, Chairman of ECO Animal Health Group plc said, “This is an important milestone in the development of ECO-Pharm Limited. Swine vaccines account for half the animal health market for this species in Japan and almost a quarter of this market in Brazil.”
Colin Gray, President and CEO of Pharmgate commented, “Our timely entry into these two important swine health markets is evidence of our shared commitment to deliver products and services that work for farmers, veterinarians and the animals they care for. Our companies are built on the quality of our products and the depth of our technical knowledge and field support. This joint venture brings these qualities together to benefit our customers around the world.”
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.
Contacts:
ECO Animal Health Group plc
| Peter Lawrence | 020 8336 6190 | |
| Marc Loomes | 020 8447 6906 | |
| Spiro Financial | ||
| Anthony Spiro | 020 8336 6196 | |
| N+1 Singer (Nominated Adviser) | 020 7496 3000 | |
| Mark Taylor, Brough Ransom | ||
| Peel Hunt LLP (Joint Broker) | ||
| James Steel, Dr Christopher Golden | 020 7418 8900 | |
About ECO Animal Health Ltd
ECO Animal Health based in London U.K. is a leader in the development, registration and marketing of pharmaceutical products for global animal health markets. Its products for these growth markets promote well-being in animals and include the novel antimicrobial, Aivlosin®, as well as a range of generic therapeutic products.
About Pharmgate LLC
Pharmgate LLC is the majority-owned US subsidiary of Jinhe Biotechnology Co., Ltd., P. R. China, the world leader in the production of chlortetracycline and other fermentation compounds, and more recently, the majority owner of Hangzhou UBEN Animal Vaccine Co., Ltd., a company manufacturing and supplying vaccines to the domestic market in China.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181106006049/en/
Copyright Business Wire 2018